Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by GW&K Investment Management LLC

GW&K Investment Management LLC boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 26.6% in the fourth quarter, HoldingsChannel reports. The firm owned 464,003 shares of the specialty pharmaceutical company’s stock after buying an additional 97,589 shares during the period. GW&K Investment Management LLC’s holdings in Jazz Pharmaceuticals were worth $57,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in JAZZ. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after buying an additional 115,102 shares during the period. Franklin Resources Inc. raised its position in Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its holdings in Jazz Pharmaceuticals by 8.3% in the third quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock valued at $87,035,000 after acquiring an additional 59,685 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Jazz Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after acquiring an additional 42,587 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Jazz Pharmaceuticals by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company’s stock worth $58,835,000 after purchasing an additional 24,481 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 5,053 shares of company stock worth $617,442 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on JAZZ shares. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday. Robert W. Baird lifted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Needham & Company LLC increased their target price on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Finally, Barclays reaffirmed an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $182.47.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $143.27 on Friday. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a 50 day moving average price of $125.87 and a 200 day moving average price of $118.62. The stock has a market capitalization of $8.66 billion, a P/E ratio of 20.18, a PEG ratio of 1.04 and a beta of 0.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.